Isn't that very similar to what Theranos was supposed to be doing?
Theranos was claiming they were already delivering the full spectrum of tests when the promise is still not fullfillable.
Alternatively, realistically focusing on a single miniaturized test or two until you get consistency with the established reference instruments could provide the foundation for a worthwhile investment by comparison.